1 / 10

Module 3 Evaluation unit

Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis. Module 3 Evaluation unit. Learning objectives. By the end of this module, you should understand: How to define a survey area, known as an evaluation unit (EU). Overview.

magee
Download Presentation

Module 3 Evaluation unit

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 3 Evaluation unit

  2. Learning objectives By the end of this module, you should understand: • How to define a survey area, known as an evaluation unit(EU).

  3. Overview • Survey area for a TAS • Defining an EU • Combining IUs • Dividing IU • Geographical area of an EU

  4. Survey area for a TAS • If all the data from relevant IUs confirm that they are eligible for a TAS, planning can begin. • The first step in designing a TAS is to define the survey area. Evaluation unit 1. Survey area 2. Survey site School Community 3. Sampling strategy Systematic sampling Cluster-based sampling Census 4. Sample size Sample size and critical cut-off

  5. Survey area for a TAS • Implementation unit (IU): The administrative unit in a country used for MDA • Evaluation unit (EU): An area selected for a TAS

  6. Defining an EU IUs within an EU can be combined, divided or remain the same, but all IUs in a country in which MDA is conducted must be included in a TAS. • IUs in an EU are usually contiguous. • All IUs in an EU should have had at least five effective rounds of MDA (i.e. ≥ 65% total population) and meet all the eligibility criteria for conducting a TAS. • All areas in the EU should have similar epidemiological features and LF transmission dynamics (e.g. epidemiological drug coverage, baseline prevalence, prevalence of Mf or Ag in sentinel and spot-check sites, principal parasites, vector abundance). • The population should not exceed 2 million.

  7. Combining IUs 2 1 Endemic IU 3 MDA

  8. Dividing an IU Endemic IU MDA 2 1 3

  9. Geographical area of an EU • Although there is no upper limit to the geographical area of an EU, the following considerations should be taken into account when combining IUs: • The probability that foci of infection will be missed increases as the geographical area of the EU increases. • Covering a larger area during the survey may increase logistical requirements (e.g. transport costs).

  10. Exercise Using existing data (e.g. maps, list of IUs, population sizes, number of rounds of MDA and coverage). • Define an appropriate EU(s). Note: Some of the data will have been reported on the ‘ELIGIBILITY’ worksheet of the TAS Eligibility and Reporting Form • Present the defined EU(s) to the group.

More Related